Christian Posern , Benjamin Dreyer , Sarah L. Maier , Florian Eichler , Michael H. Gelb , René Santer , Annette Bley , Simona Murko
{"title":"Quantification of N-acetyl-l-aspartate in dried blood spots: A simple and fast LC-MS/MS neonatal screening method for the diagnosis of Canavan disease","authors":"Christian Posern , Benjamin Dreyer , Sarah L. Maier , Florian Eichler , Michael H. Gelb , René Santer , Annette Bley , Simona Murko","doi":"10.1016/j.ymgme.2024.108489","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Canavan disease is a devastating neurometabolic disorder caused by accumulation of <em>N</em> acetylaspartate in brain and body fluids due to genetic defects in the aspartoacylase gene (<em>ASPA</em>). New gene therapies are on the horizon but will require early presymptomatic diagnosis to be fully effective.</p></div><div><h3>Methods</h3><p>We therefore developed a fast and highly sensitive liquid chromatography mass spectrometry (LC-MS/MS)-based method for quantification of <em>N</em>-acetylaspartate in dried blood spots and established reference ranges for neonates and older controls. With this test, we investigated 45 samples of 25 Canavan patients including 8 with a neonatal sample.</p></div><div><h3>Results</h3><p>Measuring <em>N</em>-acetylaspartate concentration in dried blood with this novel test, all Canavan patients (with variable severity) were well separated from the control group (median; range: 5.7; 1.6–13.6 μmol/L [<em>n</em> = 45] <em>vs</em> 0.44; 0.24–0.99 μmol/L [<em>n</em> = 59] (<em>p</em> < 0.05)). There was also no overlap when comparing neonatal samples of Canavan patients (7.3; 5.1–9.9 μmol/L [<em>n</em> = 8]) and neonatal controls (0.93; 0.4–1.8 μmol/L [<em>n</em> = 784]) (p < 0.05).</p></div><div><h3>Conclusions</h3><p>We have developed a new LC-MS/MS-based screening test for early postnatal diagnosis of Canavan disease that should be further evaluated in a population-based study once a promising treatment becomes available. The method meets the general requirements of newborn screening and should be appropriate for multiplexing with other screening approaches that combine chromatographic and mass spectrometry techniques.</p></div>","PeriodicalId":18937,"journal":{"name":"Molecular genetics and metabolism","volume":"142 2","pages":"Article 108489"},"PeriodicalIF":3.7000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096719224003731/pdfft?md5=1dea0f8fc69b0aeaadc13dc8e0e625fa&pid=1-s2.0-S1096719224003731-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular genetics and metabolism","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096719224003731","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Canavan disease is a devastating neurometabolic disorder caused by accumulation of N acetylaspartate in brain and body fluids due to genetic defects in the aspartoacylase gene (ASPA). New gene therapies are on the horizon but will require early presymptomatic diagnosis to be fully effective.
Methods
We therefore developed a fast and highly sensitive liquid chromatography mass spectrometry (LC-MS/MS)-based method for quantification of N-acetylaspartate in dried blood spots and established reference ranges for neonates and older controls. With this test, we investigated 45 samples of 25 Canavan patients including 8 with a neonatal sample.
Results
Measuring N-acetylaspartate concentration in dried blood with this novel test, all Canavan patients (with variable severity) were well separated from the control group (median; range: 5.7; 1.6–13.6 μmol/L [n = 45] vs 0.44; 0.24–0.99 μmol/L [n = 59] (p < 0.05)). There was also no overlap when comparing neonatal samples of Canavan patients (7.3; 5.1–9.9 μmol/L [n = 8]) and neonatal controls (0.93; 0.4–1.8 μmol/L [n = 784]) (p < 0.05).
Conclusions
We have developed a new LC-MS/MS-based screening test for early postnatal diagnosis of Canavan disease that should be further evaluated in a population-based study once a promising treatment becomes available. The method meets the general requirements of newborn screening and should be appropriate for multiplexing with other screening approaches that combine chromatographic and mass spectrometry techniques.
期刊介绍:
Molecular Genetics and Metabolism contributes to the understanding of the metabolic and molecular basis of disease. This peer reviewed journal publishes articles describing investigations that use the tools of biochemical genetics and molecular genetics for studies of normal and disease states in humans and animal models.